1. Home
  2. AARD vs EARN Comparison

AARD vs EARN Comparison

Compare AARD & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

N/A

Current Price

$6.07

Market Cap

165.8M

Sector

Health Care

ML Signal

N/A

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

N/A

Current Price

$4.32

Market Cap

169.8M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
AARD
EARN
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
165.8M
169.8M
IPO Year
2025
2012

Fundamental Metrics

Financial Performance
Metric
AARD
EARN
Price
$6.07
$4.32
Analyst Decision
Buy
Buy
Analyst Count
9
2
Target Price
$15.29
$5.38
AVG Volume (30 Days)
116.4K
400.2K
Earning Date
05-14-2026
06-16-2026
Dividend Yield
N/A
20.51%
EPS Growth
43.11
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$7.69
Revenue Next Year
N/A
$19.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.35
$4.25
52 Week High
$17.94
$5.77

Technical Indicators

Market Signals
Indicator
AARD
EARN
Relative Strength Index (RSI) 46.68 41.03
Support Level $5.12 $4.29
Resistance Level $6.43 $4.48
Average True Range (ATR) 0.83 0.07
MACD -0.13 -0.00
Stochastic Oscillator 36.65 5.00

Price Performance

Historical Comparison
AARD
EARN

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.

Share on Social Networks: